Selenium
tegen borstkanker.*
Vrouwen die geboren zijn met een genetische afwijking in het BRCA1 gen hebben een groter risico op borst- of baarmoederkanker. Dit gen is onder meer verantwoordelijk voor het repareren van DNA-schade. Nu is gebleken dat enige maanden supplementering van het mineraal Selenium deze DNA-schade grotendeels kan verhinderen.
Increased
Rates of Chromosome Breakage in BRCA1 Carriers Are Normalized by Oral Selenium
Supplementation
Elzbieta Kowalska1, Steven A. Narod2,
Tomasz Huzarski1, Stanislaw Zajaczek1, Jowita Huzarska1,
Bohdan Gorski1 and Jan Lubinski1
1 Department of Genetics and Pathology,
Hereditary Cancer Centre, Pomeranian Academy of Medicine, Szczecin, Poland and 2
Centre for Research on Women's Health, Sunnybrook and Women's College Health
Sciences Centre, Toronto, Ontario, Canada
Requests for reprints:
Steven Narod, Centre for Research in Women's Health, 790 Bay Street, Toronto,
Ontario, Canada, M5G 1N8. Phone: 416-351-3675; Fax: 416-351-3766. E-mail:
steven.narod@sw.ca
Women
who are born with constitutional heterozygous mutations of the BRCA1
gene face greatly increased risks of breast and ovarian cancer. The
product of the BRCA1 gene is involved in the repair of
double-stranded DNA breaks and it is believed that increased
susceptibility to DNA breakage contributes to the cancer phenotype.
It is hoped therefore that preventive strategies designed to reduce
chromosome damage will also reduce the rate of cancer in these women.
To test for increased mutagenicity of cells from BRCA1
carriers, the frequency of chromosome breaks was measured in cultured
blood lymphocytes following in vitro exposure to bleomycin in
female BRCA1 carriers and was compared with noncarrier
relatives. The frequency of chromosome breaks was also measured in BRCA1
carriers following oral selenium supplementation. Carriers of BRCA1
mutations showed significantly greater mean frequencies of induced
chromosome breaks per cell than did healthy noncarrier relatives
(0.58 versus 0.39; P < 10–4). The frequency of
chromosome breaks was greatly reduced following 1 to 3 months of oral
selenium supplementation (mean, 0.63 breaks per cell versus 0.40; P
< 10–10). The mean level of chromosome breaks in
carriers following supplementation was similar to that of the
noncarrier controls (0.40 versus 0.39). Oral selenium is a good
candidate for chemoprevention in women who carry a mutation in the BRCA1
gene.
Cancer Epidemiology Biomarkers & Prevention Vol. 14, 1302-1306 ( Sept. 2005) (Opm. Selenium is een co-factor voor de aanmaak van glutathion.)